Clone NAM10-6G4 produces mouse IgG2a immunoglobulins directed against the human CD235a antigen (41 kDa) which is expressed as a cell surface sialoglycoprotein. This antibody may be effectively used for differentiation in acute leukemias, e.g. presence of the GpA antigen on leukemia cells indicates an early erythroid cell lineage of the tumor cells. Using the CD235a antibody, a distinction can be made between erythroleukemia and other (acute) leukemias like e.g. myeloid, lymphoid or undifferentiated leukemias [3,4]. CD235a is often used in combination with detection of H-antigen and/or anti-CD36 antibodies for additional characterization of early erythroid cells. Additional immunophenotyping of early erythroleukemias can be performed by detecting myeloid-associated antigens such as CD13, CD14, CD15, CD33 and CD34, to discriminate from lymphoid lineage-associated antigens like CD2, CD7, CD10 and CD19 [6].
Glycophorin A (GpA) antigen (CD235a) is exclusively expressed on human erythroid cells and their progenitors and not on lymphoid or granulocytic progenitor cells and therefore is a very useful marker for detection of the erythroid cell lineage [1,2]. CD235a seems to be absent from erythroid colony forming cells in bone marrow, but is present during maturation from (pro-)erythroid blast cells to mature erythrocytes. CD235a is clinically important in the classification of leukemias.Synonyms: GPA, Glycophorin-A, MN sialoglycoprotein, PAS-2, Sialoglycoprotein alpha